Join Paid Research Studies for Chronic Illness in Australia

A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children

Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: MEDI8897; Drug: Palivizumab
Sponsor: MedImmune LLC
Recruiting
Late Effects After Treatment in Patients With Previously Diagnosed High-Risk Neuroblastoma

Conditions: Recurrent Neuroblastoma; Stage 2A Neuroblastoma; Stage 2B Neuroblastoma; Stage 3 Neuroblastoma; Stage 4 Neuroblastoma; Stage 4S Neuroblastoma
Interventions: Other: Cytology Specimen Collection Procedure; Other: Laboratory Biomarker Analysis; Other: Quality-of-Life Assessment
Sponsors: Children's Oncology Group; National Cancer Institute (NCI)
Recruiting
LYR-210 Depot (LYR-210) for Adult Subjects With Chronic Sinusitis

Conditions: Chronic Sinusitis; Chronic Rhinosinusitis (Diagnosis)
Interventions: Drug: LYR-210; Other: Sham comparator
Sponsor: Lyra Therapeutics
Recruiting
A Study to Evaluate the Safety and Efficacy of Upadacitinib in Participants With Giant Cell Arteritis

Condition: Giant Cell Arteritis (GCA)
Interventions: Drug: Upadacitinib; Drug: Corticosteroid (CS); Other: Placebo
Sponsor: AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy

Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Recruiting
A Study to Evaluate the Efficacy and Safety of PF-06700841 in Subjects With Active Psoriatic Arthritis

Condition: Psoriatic Arthritis
Interventions: Drug: PF-06700841; Other: Placebo
Sponsor: Pfizer
Recruiting
A Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Biologic Therapy

Condition: Crohn's Disease
Interventions: Other: Matching placebo for upadacitinib; Drug: upadacitinib
Sponsor: AbbVie
Recruiting
A Study to Assess the Efficacy and Safety of BIVV009 (Sutimlimab) in Participants With Primary Cold Agglutinin Disease Without A Recent History of Blood Transfusion (Cadenza Study)

Condition: Agglutinin Disease, Cold
Interventions: Drug: Sutimlimab; Drug: Placebo
Sponsor: Bioverativ Therapeutics Inc.
Recruiting
A Study of the Efficacy and Safety of Upadacitnib (ABT-494) in Subjects With Moderately to Severely Active Crohn's Disease Who Have Inadequately Responded to or Are Intolerant to Conventional and/or Biologic Therapies

Condition: Crohn's Disease
Interventions: Drug: Upadacitinib; Drug: Placebo for Upadacitinib
Sponsor: AbbVie
Recruiting
A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)

Condition: Psoriatic Arthritis
Interventions: Biological: placebo for rizankizumab; Biological: risankizumab
Sponsor: AbbVie
Recruiting
A Study Evaluating the Safety and Efficacy of Idasanutlin in Combination With Cytarabine and Daunorubicin in Patients Newly Diagnosed With Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission

Condition: Acute Myeloid Leukemia
Interventions: Drug: Idasanutlin; Drug: Cytarabine; Drug: Daunorubicin; Procedure: Allogeneic Hematopoietic Stem Cell Transplant (Allo-HSCT)
Sponsor: Hoffmann-La Roche
Recruiting
A Study to Investigate the Safety and Efficacy of ABBV-105 and Upadacitinib Given Alone or in Combination in Participants With Moderately to Severely Active Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus (SLE)
Interventions: Drug: ABBV-105; Drug: Placebo for ABBV-105; Drug: Upadacitinib; Drug: Placebo for upadacitinib
Sponsor: AbbVie
Recruiting
A Study of the Efficacy and Safety of Risankizumab in Subjects With Crohn's Disease Who Responded to Induction Treatment in M16-006 or M15-991; or Completed M15-989

Condition: Crohn's Disease
Interventions: Drug: placebo for risankizumab SC; Drug: risankizumab IV; Drug: placebo for risankizumab IV; Drug: risankizumab SC
Sponsor: AbbVie
Recruiting
JAK1 Inhibitor With Medicated Topical Therapy in Adolescents With Atopic Dermatitis

Condition: Atopic Dermatitis
Interventions: Drug: Placebo; Drug: PF-04965842; Drug: PF04965842
Sponsor: Pfizer
Recruiting
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus

Condition: Systemic Lupus Erythematosus
Interventions: Drug: Baricitinib; Drug: Placebo
Sponsors: Eli Lilly and Company; Incyte Corporation
Recruiting
Sentinel Node Biopsy in Endometrial Cancer

Conditions: Endometrial Cancer Stage I; Sentinel Lymph Node; Surgery
Interventions: Procedure: TH BSO with SNB; Procedure: TH BSO without retroperitoneal node dissection
Sponsors: Queensland Centre for Gynaecological Cancer; The University of Queensland
Not yet recruiting
A Study to Evaluate the Safety and Efficacy of MEDI8897 for the Prevention of Medically Attended RSV LRTI in Healthy Late Preterm and Term Infants

Condition: Respiratory Syncytial Virus Infections
Interventions: Drug: MEDI8897; Drug: Placebo
Sponsor: MedImmune LLC
Recruiting
INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer

Condition: Prostate Cancer Metastatic
Interventions: Behavioral: High intensity aerobic and resistance training; Behavioral: Psychosocial support
Sponsors: Movember Foundation; University of California, San Francisco; Edith Cowan University; King's College London; Centre hospitalier de l'Université de Montréal (CHUM); Epworth Foundation
Recruiting

Join Paid Research Studies for Chronic Illness in Australia

Welcome to Paid Research Studies